Drug Delivery System Based on Near-Infrared Light-Responsive Molybdenum Disulfide Nanosheets Controls the High-Efficiency Release of Dexamethasone To Inhibit Inflammation and Treat Osteoarthritis
Drug Delivery System Based on Near-Infrared Light-Responsive Molybdenum Disulfide Nanosheets Controls the High-Efficiency Release of Dexamethasone To Inhibit Inflammation and Treat Osteoarthritis
复制标题
基于近红外光响应二硫化钼纳米片的给药系统控制地塞米松高效释放抑制炎症和治疗骨关节炎
DOI：
10.1021/acsami.8b20372
复制
发表时间：
2019
影响因子：
9.5
通讯作者：
Liu Jie
中科院分区：
文献类型：
--
作者：
Zhao Yingyu;Wei Chunfang;Chen Xu;Liu Jiawei;Yu Qianqian;Liu Yanan;Liu Jie
关节内注射在治疗骨关节炎（OA）方面具有独特的优势，尽管它存在治疗药物在关节腔内快速清除的风险。将治疗剂与功能化纳米载体相结合可以提供有效的解决方案。通过载药纳米系统控制关节腔内药物的治疗浓度，可以协同治疗OA。在这里，我们提出了一种关节内药物递送纳米系统MoS2@CS@Dex（MCD），使用壳聚糖（CS）修饰的二硫化钼（MoS2）纳米片作为近红外（NIR）光响应载体，负载抗炎药物地塞米松（Dex）。 MCD 在体外和体内均对近红外光做出响应，并通过光热转换触发 Dex 释放。通过调整近红外光的辐射行为，可以远程控制关节腔中的 Dex 释放。 MCD延长了Dex在关节腔内的停留时间。关节内注射MCD联合NIR辐射确保了Dex在低全身剂量下的治疗效果显着增加，减轻了TNF-α和IL-1β等炎症因子分泌引起的OA软骨侵蚀。体内代谢过程中对其他内脏器官的毒性和副作用减少。此外，利用MoS2纳米片的光声成像能力来检测关节腔内MCD的代谢情况。我们的研究表明 MCD 具有治疗 OA 的巨大潜力。
Intra-articular injection has unique advantages in the treatment of osteoarthritis (OA), although it risks rapid clearance of the therapeutic drugs in the joint cavity. Combining therapeutic agents with functionalized nanocarriers may provide an effective solution. Controlling the therapeutic concentration of the drug in the joint cavity through the drug-loading nanosystem can synergistically treat OA. Here, we proposed an intra-articular drug delivery nanosystem MoS2@CS@Dex (MCD), using the chitosan (CS)-modified molybdenum disulfide (MoS2) nanosheets as near-infrared (NIR) photo-responsive carriers, loaded with the anti-inflammatory drug dexamethasone (Dex). MCD responded to NIR light both in vitro and in vivo and triggered Dex release through photothermal conversion. This enabled the remote-controlled Dex release in the joint cavity by adjusting the radiation behavior of the NIR light. MCD prolonged the residence time of Dex in the joint cavity. The intra-articular injection of MCD in combination with NIR radiation ensured a significant increase in the therapeutic effect of Dex at low systemic doses, which attenuated the cartilage erosion in the OA caused by the secretion of inflammatory factors including TNF-α and IL-1β. The toxicity and side effects on other internal organs during metabolism were reduced in the body. In addition, the photoacoustic imaging capability of MoS2nanosheets was used to detect the metabolism of MCD in the joint cavity. Our research indicated that MCD has great potential to treat OA.